Indian Journal of Urology Users online:819  
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size

    Article Cited by others


Systemic therapy in bladder cancer

Pinto Ian G

Year : 2017| Volume: 33| Issue : 2 | Page no: 118-126

   This article has been cited by
1 PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth
Sayani Bhattacharjee, Matthew J. Sullivan, Rebecca R. Wynn, Alex Demagall, Andrew S. Hendrix, Puneet Sindhwani, Firas G. Petros, Nagalakshmi Nadiminty
BMC Cancer. 2022; 22(1)
[Pubmed]  [Google Scholar] [DOI]
2 Hypermethylated in cancer 1 (HIC1) suppresses bladder cancer progression by targeting yes-associated protein (YAP) pathway
Xiaoguang Zhou, Peng Zhang, Hu Han, Hongen Lei, Xiaodong Zhang
Journal of Cellular Biochemistry. 2019; 120(4): 6471
[Pubmed]  [Google Scholar] [DOI]
3 Identification of differentially expressed genes and biological pathways in bladder cancer
Fucai Tang, Zhaohui He, Hanqi Lei, Yuehan Chen, Zechao Lu, Guohua Zeng, Hangtao Wang
Molecular Medicine Reports. 2018;
[Pubmed]  [Google Scholar] [DOI]
4 RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells
Jun-Feng Chen, Bi-Xia Yu, Liang Ma, Xiu-Yi Lv, Jun-Hui Jiang, Qi Ma
Oncology Letters. 2018;
[Pubmed]  [Google Scholar] [DOI]


Read this article